IVA
HEALTHCAREInventiva
$5.40-0.02 (-0.37%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IVA Today?
No stock-specific AI insight has been generated for IVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.85$7.98
$5.40
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-2.23
Dividend Yield—
Dividend / Share—
ROE-16.4%
Profit Margin—
Debt / Equity—
Trading
Volume72K
Avg Volume (10D)—
Shares Outstanding207.6M
IVA News
23 articles- Inventiva Raises €115.6 Million Through Second Tranche of Structured FinancingIdéal Investisseur·May 7, 2026
- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationYahoo Finance·Apr 22, 2026
- Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranorGlobeNewswire Inc.·Apr 22, 2026
- Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of LanifibranorGlobeNewswire Inc.·Apr 22, 2026
- Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)GlobeNewswire Inc.·Apr 8, 2026
- Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-FGlobeNewswire Inc.·Apr 8, 2026
- How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst RevisionsYahoo Finance·Apr 7, 2026
- Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...Yahoo Finance·Apr 2, 2026
- Inventiva Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- Inventiva reports 2025 full year results and provides a business updateYahoo Finance·Mar 30, 2026
- Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial ResultsYahoo Finance·Mar 23, 2026
- Assessing Inventiva (ENXTPA:IVA) Valuation After A Strong 12‑Month Rebound In Shareholder ReturnsYahoo Finance·Feb 28, 2026
- Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?Yahoo Finance·Feb 27, 2026
- Inventiva to Participate in Four Upcoming March Investor ConferencesYahoo Finance·Feb 26, 2026
- Inventiva reports preliminary 2025¹ fiscal year financial resultsYahoo Finance·Feb 17, 2026
- Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2Marketbeat·Feb 14, 2026
- Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Assessing Inventiva (ENXTPA:IVA) Valuation After A 126% One Year Total ReturnYahoo Finance·Jan 30, 2026
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxYahoo Finance·Jan 26, 2026
- Are You Looking for a Top Momentum Pick? Why Inventiva S.A. Sponsored ADR (IVA) is a Great ChoiceYahoo Finance·Jan 26, 2026
- Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should KnowYahoo Finance·Jan 8, 2026
- How New Data and Valuation Shifts Are Rewriting the Narrative for InventivaYahoo Finance·Dec 25, 2025
- This is Why Wall Street is Bullish on Inventiva S.A. (IVA)Yahoo Finance·Dec 18, 2025
All 23 articles loaded
Price Data
Open$5.42
Previous Close$5.42
Day High$5.46
Day Low$5.29
52 Week High$7.98
52 Week Low$2.85
52-Week Range
$2.85$7.98
$5.40
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-2.23
Dividend Yield—
Dividend / Share—
ROE-16.4%
Profit Margin—
Debt / Equity—
Trading
Volume72K
Avg Volume (10D)—
Shares Outstanding207.6M
About Inventiva
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—